Bonfiglio is known for raising capital,
building start-ups, and leading successful biotech companies as CEO
and COO.
LAS
VEGAS, March 23, 2023 /PRNewswire/ -- JanOne
(Nasdaq: JAN), a biopharmaceutical company specializing in
developing non-addicting pain killers and treatments for underlying
causes of pain, announced the hiring of John N. Bonfiglio, PhD, as interim president of
its JanOne Biotech subsidiary. JanOne Biotech focuses on pain
management for diabetic neuropathy, Peripheral Artery Disease
(PAD), and other chronic pain conditions using innovative
treatments developed by JanOne Inc.
Bonfiglio is known for raising capital,
building start-ups, and leading successful biotech companies as CEO
and COO.
Dr. Bonfiglio is a veteran leader in the biotech industry with a
track record of raising capital, building start-ups and excelling
in C-suite roles. After spending his early career at Allergan
Pharmaceuticals and Baxter HealthCare, he turned to discovering,
promoting and leading smaller biotech ventures. He was CEO at
Peregrine Pharmaceuticals where he turned around the financially
strapped public company.
During more than thirty years in the industry, his notable
achievements include helping Cypress Bioscience reinvent itself as
a neuro-pharmaceutical company and, as CEO of Immune Response
Corporation, raising more than $50
million and restarting clinical trials in HIV and MS.
Currently he is a board member for Avipero and executive board
member for Sequella, a US- based biotech company.
Tony Isaac, JanOne's CEO,
welcomed Bonfiglio to JanOne's top management. He said, "We are
delighted and honored to have Dr. Bonfiglio join us. His experience
in running public biotech companies will prove invaluable to the
progress of JanOne. Our entire team looks forward to working with
him."
Dr. Bonfiglio expressed his "goals for collaborating with the
well-respected scientific team at JanOne." He said, "We will plot a
course for the approval of important therapies in the area of pain
management and peripheral artery disease. The technologies
will meet unmet medical needs and relieve avoidable patient
suffering. I am excited by JanOne's potential to be successful in
these areas."
Forward Looking Statements
This press release contains statements that are forward-looking
statements as defined within the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
relating to the statements that JAN 101 will treat PAD, that JAN
123 will treat CRPS, the timing of the commencement of further
clinical trials, that the FDA will permit approval through a
505(b)(2) pathway for JAN 123, that upon approval JAN 101 will
immediately disrupt the PAD market, and other statements, including
words such as "continue", "expect", "intend", "will", "hope"
"should", "would", "may", "potential" and other similar
expressions. Such statements reflect JanOne's current view
with respect to future events, are subject to risks and
uncertainties, and are necessarily based upon a number of estimates
and assumptions that, while considered reasonable by JanOne, are
inherently subject to significant business, economic, competitive,
political and social uncertainties and contingencies. Many factors
could cause JanOne's actual results, performance or achievements to
be materially different from any future results, performance or
achievements described in this press release. Such factors could
include, among others, those detailed in the Company's periodic
reports filed with the Securities and Exchange Commission (the
"SEC").
Should one or more of these risks or uncertainties materialize,
or should the assumptions set out in the section entitled "Risk
Factors" in JanOne's filings with the SEC underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this press release and JanOne
does not intend, and does not assume any obligation, to update
these forward-looking statements, except as required by law. JanOne
cannot assure that such statements will prove to be accurate as
actual results and future events could differ materially from those
anticipated in such statements. Individuals are cautioned that
forward-looking statements are not guarantees of future performance
and accordingly investors are cautioned not to put undue reliance
on forward-looking statements due to the inherent uncertainty
therein.
About JanOne Inc.
JanOne is a unique Nasdaq-listed company offering innovative,
actionable solutions that it believes can help end the opioid
crisis. JanOne is dedicated to funding resources toward innovation,
technology and education to find a key resolution to the national
opioid epidemic, which is one of the deadliest and most widespread
in the nation's history. Its drugs in the clinical trial pipeline
have shown promise for their innovative targeting of the causes of
pain as a strategic option for physicians averse to exposing
patients to addictive opioids.
Please visit www.janone.com for additional information.
Media Contact:
ir@janone.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/janone-welcomes-john-bonfiglio--veteran-biotech-executive-deal-maker-and-strategist--to-top-management-team-301779498.html
SOURCE JanOne Inc.